New research published in Blood found that stem cell transplantation was the most cost-effective treatment option for adults living with sickle cell disease compared with gene therapy and standard of care.
Read more š https://ow.ly/eiQj50Z7aPU
#HemeSky #ConquerSCD Blood Journals Portfolio
ASH has announced new names for several honorific awards recognizing pioneers whose work transformed #hematology through research, mentorship, equity, and clinical care. Learn more in ASH Clinical News: https://ow.ly/6B3n50Z8LuX
#ASHAwards #HemeSky
ASH has renamed several honorific awards to recognize leaders whose work helped shape modern hematology. The updated names honor lasting contributions across research, mentorship, equity, and clinical care. š https://ow.ly/ACU350Z6eRq
#ASHAwards #HemeSky
How does extracellular sickle hemoglobin contribute to liver damage?
Join this month's Journal Club to explore the cellular pathways involved and potential therapeutic implications. https://ow.ly/bJpM50Z9vW0
#HemeSky #ConquerSCD Blood Journals Portfolio
Donāt miss the next ASH Journal Club exploring how transcription-replication conflicts (TRCs) may represent a therapeutic vulnerability in multiple myeloma & why G4 stabilizers are generating excitement as a potential treatment strategy. š https://ow.ly/Rf7g50Z5ez7
#HemeSky #MMsm #MedSky
š¢ Reminder: CRTI applications are open! Fellows & early- to mid-career #hematology faculty in Latin America, Asia-Pacific, & MMENA can apply for training in clinical trial design, patient-oriented research, mentorship, & more! Apply now! š https://ow.ly/8IuA50Z9xPC
#ASHTrainee #HemeSky #MedSky
Abstract submissions are now open for #ASH26! Your research could shape future discoveries, influence the care of patients, and drive breakthroughs in hematology.
Share your work at the 68th ASH Annual Meeting and Exposition.
š https://ow.ly/UfL450Z6EZ9
#HemeSky #MedSky
